Prospective Grant of Exclusive and Co-Exclusive Licenses: In-Vivo Imaging and Radiotherapy Targeting Antigens Recognized by the B1, B3 and B5 Antibodies

Samenvatting

This is notice in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i) that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of limited field of use exclusive and co-exclusive licenses in the United States to practice the invention embodied in U.S. Patent Application Number 07/596,289 entitled ``Antibodies Specific for Normal Primate Tissue, Malignant Human Cultured Cell Lines and Human Tumors'', to NeoRx Corporation, having a place of business in Seattle, WA and ImmunoMedics, Inc., having a place of business in Morris Plains, New Jersey. The patent rights in this invention have been assigned to the United States of America. The prospective licenses will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective licenses may be granted unless, within 60 days from the date of this published notice, NIH receives written evidence and argument that establishes that the grant of the licenses would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7. (1.) NeoRx Corporation would be granted a co-exclusive license limited to the use of the mono